https://baupharma.com/news-posts/phasing-out-of-extraordinary-covid-19-regulatory-flexibilities/ 2023-07-23T19:00:23+00:00 https://baupharma.com/wp-content/uploads/2023/07/Business-Model-Canvas-ingles.jpg https://baupharma.com/news-posts/use-of-real-world-evidence-in-regulatory-decision-making-ema-publishes-review-of-its-studies/ 2023-07-23T19:00:37+00:00 https://baupharma.com/wp-content/uploads/2023/07/news-img-5.jpg https://baupharma.com/news-posts/meeting-highlights-from-the-pharmacovigilance-risk-assessment-committee-prac/ 2023-07-23T19:01:29+00:00 https://baupharma.com/wp-content/uploads/2023/07/news-img-3.jpg https://baupharma.com/news-posts/ema-statement-on-ongoing-review-of-glp-1-receptor-agonists/ 2023-07-23T19:01:44+00:00 https://baupharma.com/wp-content/uploads/2023/07/news-img-2.jpg https://baupharma.com/news-posts/meeting-highlights-from-the-committee-for-veterinary-medicinal-products-cvmp/ 2023-07-23T19:02:05+00:00 https://baupharma.com/wp-content/uploads/2023/07/news-img-1.jpg https://baupharma.com/news-posts/uk-government-initiates-consultation-on-unregulated-cosmetic-procedures/ 2023-09-04T10:42:38+00:00 https://baupharma.com/wp-content/uploads/2023/09/close-up-woman-getting-lip-filler-with-injection-scaled.jpeg https://baupharma.com/news-posts/ema-recommends-new-measures-to-prevent-topiramate-exposure-during-pregnancy/ 2023-09-04T10:42:49+00:00 https://baupharma.com/wp-content/uploads/2023/09/side-view-pregnant-woman-home-having-headache-scaled.jpeg https://baupharma.com/news-posts/doh-closes-medical-laboratory-for-violating-regulations/ 2023-09-04T10:43:50+00:00 https://baupharma.com/wp-content/uploads/2023/09/business-coworkers-discussing-new-ideas-brainstorming-together-looking-new-project-document-scaled.jpeg https://baupharma.com/news-posts/210-million-allocated-to-combat-deadly-antimicrobial-resistance/ 2023-09-04T10:44:09+00:00 https://baupharma.com/wp-content/uploads/2023/08/AMR-scaled.jpeg https://baupharma.com/news-posts/groundbreaking-research-reveals-potential-to-halve-polio-detection-times/ 2023-09-04T10:44:39+00:00 https://baupharma.com/wp-content/uploads/2023/08/polio-vaccine-scaled.jpeg https://baupharma.com/news-posts/ema-review-reveals-limited-paternal-exposure-risk-for-valproate/ 2023-09-04T10:45:18+00:00 https://baupharma.com/wp-content/uploads/2023/08/ultrasound-for-valproate-scaled.jpeg https://baupharma.com/news-posts/paving-the-way-towards-coordinated-clinical-trials-in-public-health-emergencies-in-the-eu/ 2023-09-04T10:47:27+00:00 https://baupharma.com/wp-content/uploads/2023/08/SMALL-meeting-discussion-baupharma-scaled.jpeg https://baupharma.com/news-posts/direct-healthcare-professional-communication-dhpc-on-voxzogo-vosoritide-change-to-administration-syringe-and-needle-leading-to-product-administration-in-units-u-instead-of-ml/ 2023-09-04T10:49:06+00:00 https://baupharma.com/wp-content/uploads/2023/08/syringe-baupharma-scaled-e1691570656525.jpeg https://baupharma.com/news-posts/mhra-takes-action-strengthening-anaphylaxis-emergency-guidance-amidst-rising-hospital-admissions/ 2023-09-04T10:53:51+00:00 https://baupharma.com/wp-content/uploads/2023/08/skin-allergy-reaction-test-person-s-arm-scaled.jpeg https://baupharma.com/news-posts/fda-clears-v-pro-max-2-a-breakthrough-in-sterilizing-3d-printed-healthcare-devices/ 2023-09-04T10:57:10+00:00 https://baupharma.com/wp-content/uploads/2023/08/SMALL-SURGICAL-EQUIPMENT-scaled.jpeg https://baupharma.com/news-posts/dhas-summer-training-program-empowers-emirati-students-for-success/ 2023-09-04T11:01:38+00:00 https://baupharma.com/wp-content/uploads/2023/08/young-muslim-woman-sitting-street-cafe-looking-laptop-scaled.jpeg https://baupharma.com/news-posts/gulf-health-council-launches-educational-guide-to-combat-antimicrobial-resistance/ 2023-09-04T11:02:47+00:00 https://baupharma.com/wp-content/uploads/2023/08/vecteezy_micro-organism-magnified-to-reveal-molecular-structure_24655628_765-scaled.jpeg https://baupharma.com/news-posts/youth-led-campaigns-fresh-ways-of-communicating-about-public-health-issues/ 2023-09-04T11:08:35+00:00 https://baupharma.com/wp-content/uploads/2023/08/bottom-view-people-holding-each-other-scaled.jpeg https://baupharma.com/news-posts/recall-notice-for-ketofall-0-25-mg-ml-eye-drops-solution-pa1815-002-001/ 2023-09-11T16:22:38+00:00 https://baupharma.com/wp-content/uploads/2023/09/handsome-man-using-eye-drops-close-up-scaled.jpeg https://baupharma.com/news-posts/sun-pharma-uk-ltd-medicines-recall-important-information-for-patients-and-healthcare-professionals/ 2023-09-11T16:23:13+00:00 https://baupharma.com/wp-content/uploads/2023/09/6984041-scaled.jpg https://baupharma.com/news-posts/fda-announces-key-updates-and-approvals-september-8-2023/ 2023-09-11T16:42:36+00:00 https://baupharma.com/wp-content/uploads/2023/09/vecteezy_fda-approved-rubber-stamp-seal-vector_22599367.jpg https://baupharma.com/news-posts/unlocking-the-full-picture-ema-initiates-review-of-mysimba-for-weight-management-amidst-cardiovascular-concerns/ 2023-09-19T17:02:40+00:00 https://baupharma.com/wp-content/uploads/2023/09/overweight-man-shrt-is-small-him-with-huge-belly-open-buttons-scaled.jpeg https://baupharma.com/news-posts/important-recall-notice-lipocomb-capsules-patient-level-recall/ 2023-09-19T17:55:21+00:00 https://baupharma.com/wp-content/uploads/2023/09/yellow-triangle-warning-sign-icon-isolated-scaled.jpeg https://baupharma.com/news-posts/navigating-the-delicate-balance-fluoroquinolone-antibiotics-and-their-potential-long-lasting-effects/ 2023-09-19T18:23:40+00:00 https://baupharma.com/wp-content/uploads/2023/09/medium-shot-woman-holding-thermometer-scaled.jpeg https://baupharma.com/news-posts/urgent-field-safety-corrective-action-terumo-platelet-additive-solution-t-pas/ 2023-09-25T20:41:06+00:00 https://baupharma.com/wp-content/uploads/2023/09/close-up-doctor-putting-cannula-scaled.jpeg https://baupharma.com/news-posts/ema-recommends-non-renewal-of-conditional-marketing-authorization-for-blenrep-in-multiple-myeloma-treatment/ 2023-09-26T08:17:00+00:00 https://baupharma.com/wp-content/uploads/2023/09/patient-getting-chemotherapy-treatment-scaled.jpeg https://baupharma.com/news-posts/breaking-news-fda-awards-27-million-for-rare-disease-clinical-trials/ 2023-10-03T08:22:14+00:00 https://baupharma.com/wp-content/uploads/2023/10/authorized-allowance-permission-permit-approve-concept-scaled.jpeg https://baupharma.com/news-posts/new-safety-information-for-omega-3-acid-ethyl-esters-dose-dependent-increased-risk-of-atrial-fibrillation/ 2023-10-03T08:33:43+00:00 https://baupharma.com/wp-content/uploads/2023/10/jglw_bke0_220113-scaled.jpg https://baupharma.com/news-posts/statins-and-myasthenia-gravis-new-safety-information/ 2023-10-03T08:49:19+00:00 https://baupharma.com/wp-content/uploads/2023/10/woman-s-hand-pours-medicine-pills-out-bottle-scaled.jpeg https://baupharma.com/news-posts/revolutionizing-stem-cell-treatment-a-glimpse-into-the-future-of-manufacturing-innovation/ 2023-10-11T14:52:52+00:00 https://baupharma.com/wp-content/uploads/2023/10/dna-closely-scaled.jpeg https://baupharma.com/news-posts/ema-recommends-non-renewal-of-translarna-ataluren-marketing-authorization-for-nonsense-mutation-duchenne-muscular-dystrophy/ 2023-10-11T14:53:53+00:00 https://baupharma.com/wp-content/uploads/2023/10/front-view-container-with-pills-copy-space-scaled.jpeg https://baupharma.com/news-posts/empowering-healthcare-through-innovation-fdas-new-digital-health-advisory-committee/ 2023-10-11T14:57:32+00:00 https://baupharma.com/wp-content/uploads/2023/10/medical-banner-with-doctor-holding-tablet-scaled.jpeg https://baupharma.com/news-posts/mhra-publishes-a-safety-review-on-medicines-containing-pseudoephedrine/ 2024-03-16T20:52:39+00:00 https://baupharma.com/wp-content/uploads/2024/03/Drug-safety-article-1-1.jpg https://baupharma.com/news-posts/rubidium-rb82-generator-ruby-fill-as-a-diagnostic-tool-for-imaging-of-the-heart/ 2024-03-16T20:57:18+00:00 https://baupharma.com/wp-content/uploads/2024/03/Drug-safety-article-2.jpg https://baupharma.com/news-posts/ema-and-hma-launches-a-new-catalogues-of-real-world-data-sources-and-studies/ 2024-03-16T20:59:19+00:00 https://baupharma.com/wp-content/uploads/2024/03/keep-your-health-by-diagnosis-article-2.jpg https://baupharma.com/news-posts/fda-approves-rezdiffra-resmetirom-as-first-treatment-for-patients-with-liver-scarring-due-to-fatty-liver-disease/ 2024-04-01T19:46:06+00:00 https://baupharma.com/wp-content/uploads/2024/04/FDA-treatment.webp https://baupharma.com/news-posts/prac-meeting-highlights-finds-no-link-between-mrna-covid-19-vaccines-and-postmenopausal-bleeding/ 2024-04-01T19:47:55+00:00 https://baupharma.com/wp-content/uploads/2024/04/PRAC-Covid-vaccine.webp https://baupharma.com/news-posts/fda-warns-about-potential-for-dangerous-health-effects-that-can-result-from-certain-topical-pain-relief-products/ 2024-04-14T10:07:52+00:00 https://baupharma.com/wp-content/uploads/2024/04/Attention.jpg https://baupharma.com/news-posts/no-causal-association-between-glp-1-receptor-agonists-and-suicidal-and-self-injurious-thoughts-and-actions/ 2024-05-01T15:03:50+00:00 https://baupharma.com/wp-content/uploads/2024/05/safe-unsafe-article-1.jpg https://baupharma.com/news-posts/fda-approves-new-antimicrobial-drug/ 2024-05-01T15:05:31+00:00 https://baupharma.com/wp-content/uploads/2024/05/OIP-article-2.jpg https://baupharma.com/news-posts/tga-updated-warnings-of-faricimab-vabysmo-retinal-vasculitis-risk/ 2024-05-01T15:17:49+00:00 https://baupharma.com/wp-content/uploads/2024/05/trigger-warning.jpg https://baupharma.com/news-posts/new-approved-antibiotic-to-treat-adult-patients-with-severe-infections/ 2024-05-01T15:18:44+00:00 https://baupharma.com/wp-content/uploads/2024/05/oip-article1.jpg https://baupharma.com/news-posts/etf-recommends-updating-covid-19-vaccines-to-target-new-jn-1-variant/ 2024-05-06T16:17:04+00:00 https://baupharma.com/wp-content/uploads/2024/05/ETF-recommends-updating-COVID-19-vaccines-to-target-new-JN.1-variant-article.webp https://baupharma.com/news-posts/fda-approves-new-treatment-for-uncomplicated-urinary-tract-infections/ 2024-05-06T16:18:34+00:00 https://baupharma.com/wp-content/uploads/2024/05/FDA-Approves-New-Treatment-for-Uncomplicated-Urinary-Tract-Infections.jpg https://baupharma.com/news-posts/new-formulations-approved-to-help-prevent-hiv-1-infection-in-adults-and-adolescents/ 2024-05-13T10:37:25+00:00 https://baupharma.com/wp-content/uploads/2024/05/New-formulations-approved-to-help-prevent-HIV-1-infection-in-adults-and-adolescents.jpg https://baupharma.com/news-posts/men-on-finasteride-asked-to-stay-vigilant-for-possible-psychiatric-and-sexual-side-effects/ 2024-05-13T10:38:09+00:00 https://baupharma.com/wp-content/uploads/2024/05/warning.jpg https://baupharma.com/news-posts/new-boxed-warnings-added-to-the-patient-information-leaflets-pil-of-montelukast-due-to-neuropsychiatric-reactions/ 2024-05-18T10:45:37+00:00 https://baupharma.com/wp-content/uploads/2024/05/New-boxed-warnings-added-to-the-patient-information-leaflets-PIL-of-montelukast-due-to-neuropsychiatric-reactions.jpg https://baupharma.com/news-posts/hydroxyprogesterone-caproate-medicines-to-be-suspended-from-the-eu-market/ 2024-05-18T10:50:55+00:00 https://baupharma.com/wp-content/uploads/2024/05/Highlights-from-the-Pharmacovigilance-Risk-Assessment-Committee-PRAC-13-16-May-2024-meeting-Hydroxyprogesterone-caproate-medicines-to-be-suspended-from-the-EU-market.jpg https://baupharma.com/news-posts/warnings-new-update-about-persistent-sexual-dysfunction-for-antidepressants/ 2024-05-25T16:12:37+00:00 https://baupharma.com/wp-content/uploads/2024/05/bigstock_online_update_11303201.jpg https://baupharma.com/news-posts/new-update-on-regulating-and-evaluating-digital-mental-health-technologies-dmhts/ 2024-05-25T16:15:20+00:00 https://baupharma.com/wp-content/uploads/2024/05/New-update-on-digital-mental-health-technologies-DMHTs-1.jpg https://baupharma.com/news-posts/fda-approves-bkemv-as-first-interchangeable-biosimilar-for-two-rare-diseases/ 2024-06-01T13:31:01+00:00 https://baupharma.com/wp-content/uploads/2024/06/FDA-Approves-Bkemv-as-First-Interchangeable-Biosimilar-for-Two-Rare-Diseases-e1717248574671.webp https://baupharma.com/news-posts/topical-steroids-introduction-of-new-labelling-and-a-reminder-of-severe-withdrawal-reactions/ 2024-06-01T13:33:07+00:00 https://baupharma.com/wp-content/uploads/2024/06/Topical-steroids.png https://baupharma.com/news-posts/ixchiq-to-be-the-first-vaccine-to-protect-adults-from-chikungunya/ 2024-06-09T13:01:16+00:00 https://baupharma.com/wp-content/uploads/2024/06/Highlights-from-the-Pharmacovigilance-Risk-Assessment-Committee-PRAC-13-16-May-2024-meeting-Hydroxyprogesterone-caproate-medicines-to-be-suspended-from-the-EU-market.jpg https://baupharma.com/news-posts/new-gene-therapy-treatment-durveqtix-for-haemophilia-b/ 2024-06-09T13:02:46+00:00 https://baupharma.com/wp-content/uploads/2024/06/New-gene-therapy-treatment-Durveqtix-for-haemophilia-B.jpg https://baupharma.com/news-posts/two-new-advice-pilots-to-improve-clinical-trials-in-europe/ 2024-06-22T15:50:19+00:00 https://baupharma.com/wp-content/uploads/2024/06/Two-new-advice-pilots-to-improve-clinical-trials-in-Europe.jpg https://baupharma.com/news-posts/fda-expands-approval-of-gene-therapy-for-patients-with-duchenne-muscular-dystrophy-dmd/ 2024-06-22T15:54:59+00:00 https://baupharma.com/wp-content/uploads/2024/06/FDA-Expands-Approval-of-Gene-Therapy-for-Patients-with-Duchenne-Muscular-Dystrophy-DMD.jpg https://baupharma.com/news-posts/mhra-safety-update-on-drug-interaction-between-warfarin-and-tramadol/ 2024-06-22T15:56:19+00:00 https://baupharma.com/wp-content/uploads/2024/06/MHRA-safety-update-on-drug-interaction-between-Warfarin-and-Tramadol.jpg https://baupharma.com/news-posts/revoking-the-conditional-marketing-authorisation-for-ocaliva-a-new-important-ema-recommendation/ 2024-07-01T08:31:25+00:00 https://baupharma.com/wp-content/uploads/2024/07/Revoking-the-conditional-marketing-authorisation-for-Ocaliva.webp https://baupharma.com/news-posts/ema-new-recommendation-for-winrevair-sotatercept-approval-to-treat-adult-patients-with-pulmonary-arterial-hypertension-pah/ 2024-07-01T08:39:38+00:00 https://baupharma.com/wp-content/uploads/2024/07/EMA-new-recommendation-for-Winrevair-sotatercept-approval-to-treat-adult-patients-with-pulmonary-arterial-hypertension-PAH.jpg https://baupharma.com/news-posts/first-nasal-adrenaline-spray-eurneffy-for-emergency-treatment-against-allergic-reactionsfirst-nasal-adrenaline-spray-eurneffy-for-emergency-treatment-against-allergic-reactions/ 2024-07-04T17:06:15+00:00 https://baupharma.com/wp-content/uploads/2024/07/First-nasal-adrenaline-spray-Eurneffy-for-emergency-treatment-against-allergic-reactions.jpg https://baupharma.com/news-posts/topiramate-related-new-pregnancy-prevention-measures-announced/ 2024-07-04T17:08:11+00:00 https://baupharma.com/wp-content/uploads/2024/07/Topiramate-related-new-pregnancy-prevention-measures-announced.jpg https://baupharma.com/news-posts/safety-alert-about-compounded-colic-preparations-containing-atropa-belladonna-use-in-infants-and-children/ 2024-07-14T10:55:21+00:00 https://baupharma.com/wp-content/uploads/2024/07/Safety-alert-about-compounded-colic-preparations-containing-Atropa-belladonna.jpg https://baupharma.com/news-posts/ocrelizumab-injection-approved-for-multiple-sclerosis-treatment-in-adults/ 2024-07-20T19:21:44+00:00 https://baupharma.com/wp-content/uploads/2024/07/Ocrelizumab-injection-approved-for-multiple-sclerosis-treatment-in-adults.jpg https://baupharma.com/news-posts/capivasertib-approved-to-treat-patients-with-advanced-breast-cancer/ 2024-07-20T19:23:46+00:00 https://baupharma.com/wp-content/uploads/2024/07/Capivasertib-approved-to-treat-patients-with-advanced-breast-cance.jpg https://baupharma.com/news-posts/mhra-approves-vibegron-to-treat-adult-patients-with-overactive-bladder-syndrome-oab/ 2024-07-27T13:16:42+00:00 https://baupharma.com/wp-content/uploads/2024/07/MHRA-approves-vibegron-to-treat-adult-patients-with-Overactive-Bladder-Syndrome.jpg https://baupharma.com/news-posts/mhra-approves-the-raltegravir-first-generic-medicines-to-treat-adult-and-paediatric-patients-infected-by-hiv/ 2024-08-03T14:43:34+00:00 https://baupharma.com/wp-content/uploads/2024/08/MHRA-approves-the-Raltegravir-medicines-to-treat-adult-and-paediatric-patients-infected-by-HIV.jpg https://baupharma.com/news-posts/mhra-approves-semaglutide-to-reduce-risk-of-serious-heart-problems-in-obese-or-overweight-adults/ 2024-08-03T14:45:38+00:00 https://baupharma.com/wp-content/uploads/2024/08/MHRA-approves-semaglutide-to-reduce-risk-of-serious-heart-problems.jpg https://baupharma.com/news-posts/mhra-approves-jn-1-covid-19-vaccine-for-adults-and-children-from-infancy/ 2024-08-09T18:58:50+00:00 https://baupharma.com/wp-content/uploads/2024/08/MHRA-approves-JN.1-COVID-19-vaccine-article-1.webp https://baupharma.com/news-posts/fda-approves-first-gene-therapy-to-treat-adults-with-metastatic-synovial-sarcoma/ 2024-08-09T19:01:31+00:00 https://baupharma.com/wp-content/uploads/2024/08/FDA-Approves-First-Gene-Therapy-to-Treat-Metastatic-Synovial-Sarcoma-article-2.jpg https://baupharma.com/news-posts/fda-approves-first-nalmefene-hydrochloride-auto-injector-to-reverse-opioid-overdose/ 2024-08-19T08:48:28+00:00 https://baupharma.com/wp-content/uploads/2024/08/drugs-4260911_1280.jpg https://baupharma.com/news-posts/ema-supports-pilot-for-joint-african-continental-assessment-procedures/ 2024-08-19T08:53:10+00:00 https://baupharma.com/wp-content/uploads/2024/08/image.jpg https://baupharma.com/news-posts/fda-enables-increased-access-of-syphilis-diagnosis/ 2024-08-24T10:39:05+00:00 https://baupharma.com/wp-content/uploads/2024/08/FDA-Enables-Increased-Access-of-Syphilis-Diagnosis.webp https://baupharma.com/news-posts/zolbetuximab-approved-to-treat-adults-with-stomach-or-gastro-oesophageal-junction-cancer/ 2024-08-24T10:40:44+00:00 https://baupharma.com/wp-content/uploads/2024/08/Zolbetuximab-Approved-to-Treat-Stomach-or-Gastro-oesophageal-Junction-Cancer.jpg https://baupharma.com/news-posts/lecanemab-is-now-licensed-for-adult-patients-in-the-early-stages-of-alzheimers-disease/ 2024-09-03T08:53:17+00:00 https://baupharma.com/wp-content/uploads/2024/09/Lecanemab-is-now-licensed-for-adult-patients-in-the-early-stages-of-Alzheimers-disease.jpg https://baupharma.com/news-posts/fda-clears-first-device-to-enable-automated-insulin-dosing-for-individuals-with-type-2-diabetes/ 2024-09-03T08:56:02+00:00 https://baupharma.com/wp-content/uploads/2024/09/FDA-Clears-First-Device-to-Enable-Automated-Insulin-Dosing-for-Individuals-with-Type-2-Diabetes.jpg https://baupharma.com/news-posts/harnessing-ai-in-medicines-regulation-use-of-large-language-models-llms/ 2024-09-07T16:41:51+00:00 https://baupharma.com/wp-content/uploads/2024/09/Harnessing-AI-in-medicines-regulation-use-of-large-language-models-LLMs.webp https://baupharma.com/news-posts/fda-authorizes-updated-novavax-covid-19-vaccine-to-better-protect-against-currently-circulating-variants/ 2024-09-07T16:47:23+00:00 https://baupharma.com/wp-content/uploads/2024/09/FDA-Authorizes-Updated-Novavax-COVID-19-Vaccine.jpg https://baupharma.com/news-posts/ema-recommends-measures-to-minimize-serious-outcomes-of-known-side-effect-with-painkiller-metamizole/ 2024-09-14T09:06:11+00:00 https://baupharma.com/wp-content/uploads/2024/09/EMA-recommends-measures-to-minimize-serious-outcomes-of-painkiller-metamizole.jpg https://baupharma.com/news-posts/the-mhra-finds-that-there-is-insufficient-evidence-to-establish-a-connection-between-glp-1-receptor-agonists-and-suicidal-or-self-injurious-ideas-and-behaviors/ 2024-09-14T09:17:09+00:00 https://baupharma.com/wp-content/uploads/2024/09/The-MHRA-finds-that-there-is-insufficient-evidence-to-establish-a-connection-between-GLP-1-receptor-agonists-and-suicidal-or-self-injurious-ideas-and-behaviors.jpg https://baupharma.com/news-posts/mhra-launches-new-strategy-for-improving-safety-communications/ 2024-09-21T12:06:16+00:00 https://baupharma.com/wp-content/uploads/2024/09/MHRA-launches-new-Strategy-for-Improving-Safety-Communications.png https://baupharma.com/news-posts/ema-recommends-extending-indication-of-mpox-vaccine-to-adolescents/ 2024-09-21T12:10:32+00:00 https://baupharma.com/wp-content/uploads/2024/09/EMA-recommends-extending-indication-of-mpox-vaccine-to-adolescents.jpg https://baupharma.com/news-posts/the-fda-has-approved-the-first-treatment-for-niemann-pick-disease-type-c/ 2024-09-28T13:58:43+00:00 https://baupharma.com/wp-content/uploads/2024/09/The-FDA-has-approved-the-first-treatment-for-Niemann-Pick-Disease-Type-C.jpg https://baupharma.com/news-posts/fda-approves-influenza-vaccine-for-nasal-spray-administration-by-the-patient-or-a-caregiver/ 2024-09-28T14:00:09+00:00 https://baupharma.com/wp-content/uploads/2024/09/FDA-Approves-Influenza-Vaccine-for-Nasal-Spray-Administration.jpg https://baupharma.com/news-posts/fruquintinib-approved-to-treat-adult-patients-with-metastatic-colorectal-cancer/ 2024-10-05T18:05:34+00:00 https://baupharma.com/wp-content/uploads/2024/10/Fruquintinib-approved-to-treat-adult-patients-with-metastatic-colorectal-cancer.jpg https://baupharma.com/news-posts/ema-recommends-suspension-of-sickle-cell-disease-medicine-oxbryta/ 2024-10-05T18:07:23+00:00 https://baupharma.com/wp-content/uploads/2024/10/EMA-recommends-suspension-of-sickle-cell-disease-medicine-Oxbryta.webp https://baupharma.com/news-posts/fda-approves-medicine-for-treatment-of-schizophrenia-with-new-mechanism-of-action/ 2024-10-12T16:23:18+00:00 https://baupharma.com/wp-content/uploads/2024/10/FDA-Approves-Medicine-for-Treatment-of-Schizophrenia-e1728750188923.jpg https://baupharma.com/news-posts/enhancing-the-effectiveness-of-the-eus-new-drug-approval-procedure/ 2024-10-12T16:24:44+00:00 https://baupharma.com/wp-content/uploads/2024/10/Enhancing-the-effectiveness-of-the-EUs-new-drug-approval-procedure.jpg https://baupharma.com/news-posts/mhra-approves-first-medicine-for-rare-immune-disease-apds/ 2024-10-19T11:58:02+00:00 https://baupharma.com/wp-content/uploads/2024/10/MHRA-approves-first-medicine-for-rare-immune-disease-APDS.jpg https://baupharma.com/news-posts/the-first-home-flu-and-covid-19-combination-test-is-approved-for-marketing-by-the-fda-outside-of-emergency-use-authorities/ 2024-10-19T11:59:59+00:00 https://baupharma.com/wp-content/uploads/2024/10/The-first-home-flu-and-COVID-19-combination-test-is-approved-for-marketing-by-the-FDA-outside-of-emergency-use-authorities.jpg https://baupharma.com/news-posts/patients-are-asked-by-mhra-to-promptly-report-any-safety-issues-with-their-insulin-pump-or-continuous-glucose-monitor/ 2024-10-26T12:41:40+00:00 https://baupharma.com/wp-content/uploads/2024/10/Patients-are-asked-to-report-any-safety-issues-with-their-insulin-pump-or-continuous-glucose-monitorarticle.jpg https://baupharma.com/news-posts/the-mhra-has-approved-the-adult-kp-2-covid-19-vaccination/ 2024-10-26T12:43:20+00:00 https://baupharma.com/wp-content/uploads/2024/10/Adult-KP.2-COVID-19-vaccination-approval.jpg https://baupharma.com/news-posts/fda-approves-new-treatment-for-hemophilia-a-or-b/ 2024-11-02T14:00:41+00:00 https://baupharma.com/wp-content/uploads/2024/11/FDA-Approves-New-Treatment-for-Hemophilia-A-or-B.jpg https://baupharma.com/news-posts/mhra-approved-new-treatment-for-adults-with-a-rare-liver-disease-known-as-primary-biliary-cholangitis/ 2024-11-02T14:08:55+00:00 https://baupharma.com/wp-content/uploads/2024/11/MHRA-approved-new-treatment-for-adults-with-a-rare-liver-disease-PBCMHRA-approved-new-treatment-for-adults-with-a-rare-liver-disease-PBC.jpg https://baupharma.com/news-posts/sugemalimab-is-now-approved-to-treat-non-small-cell-lung-cancer-in-adults/ 2024-11-12T10:35:34+00:00 https://baupharma.com/wp-content/uploads/2024/11/MHRA-approved-new-treatment-for-adults-with-a-rare-liver-disease-PBCMHRA-approved-new-treatment-for-adults-with-a-rare-liver-disease-PBC-1.jpg https://baupharma.com/news-posts/healthcare-professionals-are-reminded-by-mhra-to-inform-patients-about-the-negative-side-effects-of-glp-1-agonists-and-to-report-any-misuse/ 2024-11-17T13:40:15+00:00 https://baupharma.com/wp-content/uploads/2024/11/Healthcare-professionals-are-reminded-to-inform-patients-about-the-negative-side-effects-of-GLP-1-agonists-and-to-report-any-misuse.jpg https://baupharma.com/news-posts/the-fda-recommends-discontinuing-the-use-of-oral-phenylephrine-as-an-otc-monograph-nasal-decongestant-active-ingredient-following-a-thorough-review/ 2024-12-01T15:16:40+00:00 https://baupharma.com/wp-content/uploads/2024/12/The-FDA-recommends-discontinuing-the-use-of-oral-phenylephrine.png https://baupharma.com/news-posts/sparsentan-is-now-approved-to-treat-adult-patients-with-primary-immunoglobulin-a-nephropathy-igan/ 2024-12-01T15:18:11+00:00 https://baupharma.com/wp-content/uploads/2024/12/new-approval-to-treat-adult-patients-with-primary-immunoglobulin-A-nephropathy.png https://baupharma.com/news-posts/approval-of-first-gene-therapy-for-treatment-of-aromatic-l-amino-acid-decarboxylase-deficiency/ 2024-12-07T21:49:01+00:00 https://baupharma.com/wp-content/uploads/2024/12/Approval-of-First-Gene-Therapy-for-Treatment-of-AADC.jpg https://baupharma.com/news-posts/updated-advice-to-minimise-risks-of-interaction-between-weight-loss-medicine-and-opioids/ 2024-12-07T21:50:34+00:00 https://baupharma.com/wp-content/uploads/2024/12/Updated-advice-to-minimise-risks-of-interaction.jpg https://baupharma.com/news-posts/approval-of-new-diagnostic-tool-for-adult-alzheimers-disease-patients-exhibiting-cognitive-impairment/ 2024-12-14T21:07:04+00:00 https://baupharma.com/wp-content/uploads/2024/12/Approval-of-new-diagnostic-tool-for-adult-Alzheimers-disease-patients.jpg https://baupharma.com/news-posts/new-clinical-trials-framework-being-laid-in-parliament-aiming-to-help-patients-the-nhs-and-the-life-sciences-industry/ 2024-12-14T21:11:31+00:00 https://baupharma.com/wp-content/uploads/2024/12/New-clinical-trials-framework.webp https://baupharma.com/news-posts/first-advised-initial-treatment-for-rare-progressive-lung-conditions-in-children-and-adolescents/ 2024-12-22T14:49:40+00:00 https://baupharma.com/wp-content/uploads/2024/12/First-treatment-for-rare-progressive-lung-conditions-in-children-and-adolescents.jpg https://baupharma.com/news-posts/six-tips-for-remaining-safe-and-healthy-during-the-holiday-season-regarding-medications-and-medical-equipment/ 2024-12-22T14:51:46+00:00 https://baupharma.com/wp-content/uploads/2024/12/Six-tips-for-remaining-safe-and-healthy-during-the-holiday-season.webp https://baupharma.com/news-posts/initial-therapy-for-peripheral-thyrotoxicosis-in-allan-herndon-dudley-syndrome-patients/ 2024-12-29T17:18:23+00:00 https://baupharma.com/wp-content/uploads/2024/12/Initial-therapy-for-peripheral-thyrotoxicosis.webp https://baupharma.com/news-posts/the-first-medication-to-treat-a-rare-genetic-condition-that-causes-tumors-and-cysts/ 2024-12-29T17:20:36+00:00 https://baupharma.com/wp-content/uploads/2024/12/First-medication-to-treat-a-rare-genetic-condition-that-causes-tumors-and-cysts.jpg https://baupharma.com/news-posts/withdrawal-of-alofisel-from-the-eu-market/ 2025-01-05T08:46:07+00:00 https://baupharma.com/wp-content/uploads/2025/01/Withdrawal-of-Alofisel-from-the-EU-market-1.jpg https://baupharma.com/news-posts/new-treatment-approval-for-congenital-adrenal-hyperplasia/ 2025-01-05T08:49:39+00:00 https://baupharma.com/wp-content/uploads/2025/01/New-Treatment-approval-for-Congenital-Adrenal-Hyperplasia.jpg https://baupharma.com/news-posts/approval-of-mesenchymal-stromal-cell-therapy/ 2025-01-12T14:57:38+00:00 https://baupharma.com/wp-content/uploads/2025/01/Approval-of-Mesenchymal-Stromal-Cell-Therapy.webp https://baupharma.com/news-posts/conditionally-approved-treatment-for-patients-with-duchenne-muscular-dystrophy-dmd/ 2025-01-12T15:00:10+00:00 https://baupharma.com/wp-content/uploads/2025/01/conditionally-approved-treatment-for-patients-with-Duchenne-muscular-dystrophy-DMD.webp https://baupharma.com/news-posts/new-approval-for-treatment-of-adult-patients-with-small-cell-lung-cancer/ 2025-01-18T11:03:20+00:00 https://baupharma.com/wp-content/uploads/2025/01/New-treatment-of-adult-patients-with-small-cell-lung-cancer.webp https://baupharma.com/news-posts/new-publication-of-draft-guidelines-for-the-use-of-tissue-biopsies-in-clinical-research/ 2025-01-18T11:05:52+00:00 https://baupharma.com/wp-content/uploads/2025/01/New-Guidelines-for-the-Use-of-Tissue-Biopsies-in-Clinical-Research.jpg https://baupharma.com/news-posts/new-approved-treatment-for-adult-patients-with-pulmonary-arterial-hypertension-pah/ 2025-01-25T13:45:56+00:00 https://baupharma.com/wp-content/uploads/2025/01/New-approved-treatment-for-adult-patients-with-PAH.png https://baupharma.com/news-posts/highlighted-safety-warnings-about-possible-side-effects-of-montelukast/ 2025-01-25T13:51:36+00:00 https://baupharma.com/wp-content/uploads/2025/01/safety-warnings-about-possible-side-effects-of-Montelukast-1.png https://baupharma.com/news-posts/the-fda-is-suggesting-nicotine-levels-reduction/ 2025-02-02T12:10:51+00:00 https://baupharma.com/wp-content/uploads/2025/02/The-FDA-is-suggesting-nicotine-levels-reduction.webp https://baupharma.com/news-posts/new-approval-for-treatment-and-prevention-of-angioedema-attacks/ 2025-02-02T12:12:37+00:00 https://baupharma.com/wp-content/uploads/2025/02/New-approval-for-prevention-of-angioedema-attacks.jpg https://baupharma.com/news-posts/the-fda-has-approved-the-first-drug-in-a-new-class-of-non-opioid-pain-medicines/ 2025-02-08T21:43:37+00:00 https://baupharma.com/wp-content/uploads/2025/02/The-FDA-has-approved-the-first-drug-of-non-opioid-pain-medicines.jpg https://baupharma.com/news-posts/eu-agencies-collaborate-to-address-azole-fungicide-resistance/ 2025-02-08T21:45:55+00:00 https://baupharma.com/wp-content/uploads/2025/02/EU-agencies-collaborate-to-address-azole-fungicide-resistance.jpg https://baupharma.com/news-posts/new-combination-of-drugs-to-treat-parasitic-worm-infections/ 2025-02-15T12:49:08+00:00 https://baupharma.com/wp-content/uploads/2025/02/New-combination-to-treat-parasitic-worm-infections.jpg https://baupharma.com/news-posts/mhra-seeks-feedback-on-proposed-recommendations-to-facilitate-the-safe-regulation-of-emerging-personalized-cancer-medicines/ 2025-02-15T12:51:50+00:00 https://baupharma.com/wp-content/uploads/2025/02/Recommendations-to-facilitate-the-safe-regulation-of-emerging-cancer-medicines.webp https://baupharma.com/news-posts/chikungunya-vaccine-authorization-for-adults/ 2025-02-23T11:14:11+00:00 https://baupharma.com/wp-content/uploads/2025/02/Chikungunya-vaccine-authorization-for-Adults.jpg https://baupharma.com/news-posts/the-medical-imaging-agent-gozetotide-has-been-approved-for-the-diagnosis-of-prostate-cancer/ 2025-02-23T11:16:17+00:00 https://baupharma.com/wp-content/uploads/2025/02/Cancer-diagnosis.webp https://baupharma.com/news-posts/treatment-approval-for-patients-with-prurigo-nodularis-and-eczema/ 2025-03-01T21:31:41+00:00 https://baupharma.com/wp-content/uploads/2025/03/treatment-approval-for-patients-with-prurigo-nodularis-and-eczema-.webp https://baupharma.com/news-posts/the-fda-warns-patients-that-while-using-smartphone-compatible-diabetes-devices/ 2025-03-01T21:33:32+00:00 https://baupharma.com/wp-content/uploads/2025/03/The-FDA-warns-patients-that-while-using-smartphone-compatible-diabetes-devices.jpg https://baupharma.com/news-posts/the-first-rapid-acting-insulin-biosimilar-product-approved-by-the-fda-for-the-treatment-of-diabetes/ 2025-03-07T23:11:38+00:00 https://baupharma.com/wp-content/uploads/2025/03/The-first-insulin-biosimilar-product-approved-by-the-FDA.webp https://baupharma.com/news-posts/first-treatment-approval-for-cerebrotendinous-xanthomatosis-a-rare-lipid-storage-disease/ 2025-03-07T23:13:23+00:00 https://baupharma.com/wp-content/uploads/2025/03/First-Treatment-for-a-Rare-Lipid-Storage-Disease.jpg https://baupharma.com/news-posts/the-eu-has-introduced-a-new-clinical-trial-map/ 2025-03-16T01:33:50+00:00 https://baupharma.com/wp-content/uploads/2025/03/New-clinical-trial-map.jpg https://baupharma.com/news-posts/prolonged-release-opioids/ 2025-03-16T03:16:01+00:00 https://baupharma.com/wp-content/uploads/2025/03/Prolonged-release-opioids-2.jpg https://baupharma.com/news-posts/mresvia-rsv-vaccine-is-authorized-to-protect-individuals-aged-60-and-older/ 2025-03-21T23:07:40+00:00 https://baupharma.com/wp-content/uploads/2025/03/RSV-vaccine-is-authorized-to-protect-individuals-aged-60-and-older.jpg https://baupharma.com/news-posts/unregulated-pharmaceuticals-used-in-advanced-therapy-present-significant-health-hazards/ 2025-03-21T23:09:41+00:00 https://baupharma.com/wp-content/uploads/2025/03/Unregulated-pharmaceuticals-present-significant-health-hazards.jpg https://baupharma.com/news-posts/triple-combination-medication-for-cystic-fibrosis/ 2025-03-29T19:41:49+00:00 https://baupharma.com/wp-content/uploads/2025/03/Triple-combination-medication-For-cystic-fibrosis.webp https://baupharma.com/news-posts/fda-educational-efforts-prevented-young-people-from-using-e-cigarettes/ 2025-04-09T15:22:22+00:00 https://baupharma.com/wp-content/uploads/2025/03/DA-educational-efforts-prevented-about-young-people-from-using-e-cigarettes.webp https://baupharma.com/news-posts/expanded-therapeutic-use-of-kaftrio-kalydeco-in-cystic-fibrosis-patients/ 2025-04-12T15:16:25+00:00 https://baupharma.com/wp-content/uploads/2025/04/Expanded-Therapeutic-use-of-Kaftrio.webp https://baupharma.com/news-posts/new-approval-for-hard-to-treat-her2-positive-cancer-tumors/ 2025-04-19T22:13:24+00:00 https://baupharma.com/wp-content/uploads/2025/04/image.jpg https://baupharma.com/news-posts/relief-in-reach-new-promise-to-hemophilia-warriors/ 2025-04-21T11:25:37+00:00 https://baupharma.com/wp-content/uploads/2025/04/Hemophilia-Warriors-e1745101180848.png https://baupharma.com/news-posts/ema-endorses-ai-powered-tools-supporting-liver-biopsy-analyses/ 2025-04-26T17:54:40+00:00 https://baupharma.com/wp-content/uploads/2025/04/AI-liver-biobsy-analysis-article-1.png https://baupharma.com/news-posts/a-new-chapter-in-research-uk-sets-clinical-trial-standards/ 2025-04-26T18:00:34+00:00 https://baupharma.com/wp-content/uploads/2025/04/image-1.jpg https://baupharma.com/news-posts/fezolinetant-risk-of-liver-injury-minimizing-liver-risk-with-new-guidelines/ 2025-05-03T23:11:45+00:00 https://baupharma.com/wp-content/uploads/2025/05/image-e1746313897482.jpg https://baupharma.com/news-posts/smarter-pathways-to-biosimilars/ 2025-05-03T23:13:16+00:00 https://baupharma.com/wp-content/uploads/2025/05/biosimilar-article-1-1.webp https://baupharma.com/news-posts/a-new-era-in-managing-thyroid-eye-disease-patients/ 2025-05-12T09:19:36+00:00 https://baupharma.com/wp-content/uploads/2025/05/A-New-Era-in-Managing-Thyroid-Eye-Disease-Patients-scaled.jpg https://baupharma.com/news-posts/the-blue-inhaler-trap-what-every-asthma-patient-should-know/ 2025-05-16T15:36:51+00:00 https://baupharma.com/wp-content/uploads/2025/05/The-Blue-Inhaler-Trap-What-Every-Asthma-Patient-Should-Know.jpg https://baupharma.com/news-posts/hope-for-the-heart-acoramidis-approved-for-transthyretin-amyloidosis/ 2025-05-16T15:48:03+00:00 https://baupharma.com/wp-content/uploads/2025/05/Hope-For-the-Heart-Acoramidis-Approved-for-Transthyretin-Amyloidosis.webp https://baupharma.com/news-posts/faster-flexible-cancer-care-nivolumab-newest-subcutaneous-injection-approval/ 2025-05-24T18:09:21+00:00 https://baupharma.com/wp-content/uploads/2025/05/Faster-Flexible-Cancer-Care-Nivolumab-Newest-Subcutaneous-Injection-Approval.png https://baupharma.com/news-posts/rethinking-fluoride-fda-takes-a-stand-for-kids-health/ 2025-05-24T18:11:45+00:00 https://baupharma.com/wp-content/uploads/2025/05/Rethinking-Fluoride-FDA-Takes-a-Stand-for-Kids-Health-scaled.jpg https://baupharma.com/news-posts/kaftrio-serious-impact-on-mental-health/ 2025-06-01T09:37:43+00:00 https://baupharma.com/wp-content/uploads/2025/06/Kaftrio-Serious-Impact-on-Mental-health.webp https://baupharma.com/news-posts/new-breakthrough-fda-approves-new-blood-test-for-early-diagnosis-of-alzheimers/ 2025-06-05T21:41:48+00:00 https://baupharma.com/wp-content/uploads/2025/06/New-Breakthrough-FDA-Approves-New-Blood-Test-for-Early-Diagnosis-of-Alzheimers.jpg https://baupharma.com/news-posts/trixeo-aerosphere-inhaler-reformulated-for-a-cleaner-future/ 2025-06-05T21:44:33+00:00 https://baupharma.com/wp-content/uploads/2025/06/Trixeo-Aerosphere-Inhaler-Reformulated-for-A-Cleaner-Future.jpg https://baupharma.com/news-posts/mental-health-confirmed-risks-in-some-hair-loss-treatments/ 2025-06-14T20:33:09+00:00 https://baupharma.com/wp-content/uploads/2025/06/Mental-Health-confirmed-Risks-in-some-Hair-Loss-Treatments.png https://baupharma.com/news-posts/fda-embraces-ai-future-with-successful-pilot-and-bold-expansion-plan/ 2025-06-17T21:00:09+00:00 https://baupharma.com/wp-content/uploads/2025/06/FDA-Embraces-AI-Future-with-Successful-Pilot-and-Bold-Expansion-Plan.jpg https://baupharma.com/news-posts/ema-implements-new-measures-to-keep-antibiotic-resistance-under-control/ 2025-06-21T08:22:24+00:00 https://baupharma.com/wp-content/uploads/2025/06/EMA-Implements-New-Measures-to-Keep-Antibiotic-Resistance-Under-Control-e1750494132836.webp https://baupharma.com/news-posts/guselkumab-has-new-approved-indications-for-treating-crohns-disease-and-ulcerative-colitis-patients/ 2025-06-21T08:24:52+00:00 https://baupharma.com/wp-content/uploads/2025/06/new-approved-indications-for-treating-Crohns-disease-and-ulcerative-colitis-patients.webp https://baupharma.com/news-posts/accelerated-cancer-care-with-advanced-radiotherapy/ 2025-06-27T14:10:19+00:00 https://baupharma.com/wp-content/uploads/2025/06/Accelerated-Cancer-Care-with-Advanced-Radiotherapy.webp https://baupharma.com/news-posts/semaglutide-alert-rare-eye-side-effect-identified/ 2025-06-27T14:12:01+00:00 https://baupharma.com/wp-content/uploads/2025/06/Semaglutide-Alert-Rare-Eye-Side-Effect-Identified.jpg https://baupharma.com/news-posts/inclusion-of-pregnant-breastfeeding-women-in-clinical-trials/ 2025-07-03T11:09:24+00:00 https://baupharma.com/wp-content/uploads/2025/07/Inclusion-Of-Pregnant-Breastfeeding-Women-in-Clinical-Trials.jpg https://baupharma.com/news-posts/turning-point-in-cancer-care-nhs-unlocks-life-saving-innovation/ 2025-07-03T11:12:35+00:00 https://baupharma.com/wp-content/uploads/2025/07/Turning-Point-in-Cancer-Care-NHS-Unlocks-Life-Saving-Innovation-scaled.jpg https://baupharma.com/news-posts/fda-greenlights-new-triple-therapy-for-relapsed-follicular-lymphoma/ 2025-07-12T12:46:32+00:00 https://baupharma.com/wp-content/uploads/2025/07/FDA-Greenlights-New-Triple-Therapy-For-Relapsed-Follicular-Lymphoma.png https://baupharma.com/news-posts/fda-raises-heat-safety-concerns-over-scopolamine-transdermal-patch/ 2025-07-12T12:49:32+00:00 https://baupharma.com/wp-content/uploads/2025/07/FDA-Raises-Heat-Safety-Concerns-Over-Scopolamine-Transdermal-Patch.jpg https://baupharma.com/news-posts/breakthrough-stem-cell-therapy-offers-new-hope-for-blood-cancer-patients/ 2025-07-19T20:35:47+00:00 https://baupharma.com/wp-content/uploads/2025/07/Breakthrough-Stem-Cell-Therapy-Offers-New-Hope-for-Blood-Cancer-Patients.webp https://baupharma.com/news-posts/uk-leads-the-way-in-safe-ai-for-healthcare/ 2025-07-19T20:37:24+00:00 https://baupharma.com/wp-content/uploads/2025/07/UK-Leads-the-Way-in-Safe-AI-For-Healthcare.webp https://baupharma.com/news-posts/at-home-screening-of-cervical-cancer-for-better-future-of-women-health/ 2025-07-26T10:40:21+00:00 https://baupharma.com/wp-content/uploads/2025/07/At-Home-Screening-of-cervical-Cancer-for-Better-Future-of-Women-Health.png https://baupharma.com/news-posts/new-hope-for-fatty-liver-tackling-scarring-head-on/ 2025-07-26T10:42:09+00:00 https://baupharma.com/wp-content/uploads/2025/07/New-Hope-for-Fatty-Liver-Tackling-Scarring-Head-On.png https://baupharma.com/news-posts/breaking-ground-in-small-cell-lung-cancer-first-anti-pd-1-antibody-gains-uk-approval/ 2025-08-02T10:37:26+00:00 https://baupharma.com/wp-content/uploads/2025/08/Breaking-Ground-in-small-cell-lung-cancer-First-Anti-PD-1-Antibody-Gains-UK-Approval.jpg https://baupharma.com/news-posts/one-gate-less-wait-new-rules-for-radiation-protection-in-clinical-trials/ 2025-08-02T10:49:45+00:00 https://baupharma.com/wp-content/uploads/2025/08/One-Gate-Less-Wait-New-Rules-for-Radiation-Protection-in-Clinical-Trials.jpg https://baupharma.com/news-posts/fda-warns-weight-loss-risk-in-young-children-on-adhd-medications/ 2025-08-07T16:21:04+00:00 https://baupharma.com/wp-content/uploads/2025/08/FDA-Warns-Weight-Loss-Risk-in-Young-Children-on-ADHD-Medications.webp https://baupharma.com/news-posts/fda-grants-fast-track-approval-to-linvoseltamab-gcpt-for-advanced-multiple-myeloma/ 2025-08-17T09:51:34+00:00 https://baupharma.com/wp-content/uploads/2025/08/article-1-pic.jpg https://baupharma.com/news-posts/reinforcing-precautions-ixchiq-vaccine-and-immunocompromised-patients/ 2025-08-17T09:53:51+00:00 https://baupharma.com/wp-content/uploads/2025/08/Outlook-jwgxlvgh.webp https://baupharma.com/news-posts/fda-suspends-elevidys-distribution-and-trials-following-safety-concerns/ 2025-08-22T12:41:30+00:00 https://baupharma.com/wp-content/uploads/2025/08/FDA-Suspends-Elevidys-Distribution-and-Trials-Following-Safety-Concerns-e1755866479434.jpg https://baupharma.com/news-posts/mhra-greenlights-new-treatment-for-menopausal-symptoms/ 2025-08-22T12:58:52+00:00 https://baupharma.com/wp-content/uploads/2025/08/MHRA-Greenlights-New-Treatment-for-Menopausal-Symptoms-e1755867519957.jpg https://baupharma.com/news-posts/mhra-expands-bladder-cancer-treatment-choices-with-latest-approval/ 2025-08-28T09:24:22+00:00 https://baupharma.com/wp-content/uploads/2025/08/MHRA-Expands-Bladder-Cancer-Treatment-Choices-with-Latest-Approval.jpg https://baupharma.com/news-posts/first-ever-allergic-shock-treatment-in-nasal-spray-form/ 2025-08-28T09:29:15+00:00 https://baupharma.com/wp-content/uploads/2025/08/First-Ever-Allergic-Shock-Treatment-in-Nasal-Spray-Form.webp https://baupharma.com/news-posts/fda-tightens-opioid-labeling-rules-to-guide-safer-use/ 2025-09-04T12:07:50+00:00 https://baupharma.com/wp-content/uploads/2025/09/FDA-Tightens-Opioid-Labeling-Rules-to-Guide-Safer-Use.jpg https://baupharma.com/news-posts/from-delayed-to-instant-fda-opens-real-time-window-on-drug-safety/ 2025-09-12T13:35:27+00:00 https://baupharma.com/wp-content/uploads/2025/09/From-Delayed-to-Instant-FDA-Opens-Real-Time-Window-on-Drug-Safety.jpg https://baupharma.com/news-posts/evrysdi-risdiplam-omission-in-eu-product-labeling-identified/ 2025-09-17T12:06:06+00:00 https://baupharma.com/wp-content/uploads/2025/09/Evrysdi-risdiplam-Omission-in-EU-Product-Labeling-Identified-1.jpg https://baupharma.com/news-posts/when-clarity-matters-safety-updates-on-isozid-infusion-solutions/ 2025-09-19T08:42:33+00:00 https://baupharma.com/wp-content/uploads/2025/09/When-Clarity-Matters-Safety-Updates-on-ISOZID-Infusion-Solutions.jpg https://baupharma.com/news-posts/expanding-options-fda-approval-of-new-chronic-immune-thrombocytopenia-drug/ 2025-09-22T07:03:57+00:00 https://baupharma.com/wp-content/uploads/2025/09/Expanding-Options-FDA-Approval-of-New-Chronic-Immune-Thrombocytopenia-Drug.jpg https://baupharma.com/news-posts/fda-approval-offers-new-path-for-pediatric-nf1-care/ 2025-09-22T07:06:35+00:00 https://baupharma.com/wp-content/uploads/2025/09/FDA-Approval-Offers-New-Path-for-Pediatric-NF1-Care.jpg https://baupharma.com/news-posts/fda-updates-guidance-on-biosimilar-development-what-industry-needs-to-know/ 2025-09-22T07:09:51+00:00 https://baupharma.com/wp-content/uploads/2025/09/FDA-Updates-Guidance-on-Biosimilar-Development-What-Industry-Needs-to-Know.jpg https://baupharma.com/news-posts/modernizing-good-clinical-practice-to-advance-global-research/ 2025-09-22T07:12:07+00:00 https://baupharma.com/wp-content/uploads/2025/09/Modernizing-Good-Clinical-Practice-to-Advance-Global-Research-scaled.jpg https://baupharma.com/news-posts/breakthrough-us-uk-pact-promises-drug-discovery-advances-and-life-changing-impact/ 2025-09-25T14:44:24+00:00 https://baupharma.com/wp-content/uploads/2025/09/Breakthrough-US%E2%80%93UK-pact-promises-drug-discovery-advances-and-life-changing-impact.jpg https://baupharma.com/news-posts/smart-glasses-and-ai-new-vision-for-mental-health/ 2025-09-25T14:46:39+00:00 https://baupharma.com/wp-content/uploads/2025/09/Smart-Glasses-and-AI-New-Vision-for-Mental-Health.jpeg https://baupharma.com/news-posts/implied-adr-admissions-a-new-way-to-spot-drug-related-hospitalizations/ 2025-09-26T13:18:27+00:00 https://baupharma.com/wp-content/uploads/2025/09/Implied-ADR-Admissions-A-New-Way-to-Spot-Drug-Related-Hospitalizations-1.jpg https://baupharma.com/news-posts/fda-drafts-roadmap-for-safer-non-opioid-pain-treatments/ 2025-10-01T09:35:59+00:00 https://baupharma.com/wp-content/uploads/2025/10/FDA-Drafts-Roadmap-for-Safer-Non-Opioid-Pain-Treatments.jpg https://baupharma.com/news-posts/fda-expands-vonvendi-approval-to-broaden-care-for-von-willebrand-disease/ 2025-10-01T09:40:50+00:00 https://baupharma.com/wp-content/uploads/2025/10/FDA-Expands-Vonvendi-Approval-to-Broaden-Care-for-von-Willebrand-Disease.jpg https://baupharma.com/news-posts/mhra-joins-global-effort-to-approve-promising-brain-cancer-treatment/ 2025-10-01T09:48:51+00:00 https://baupharma.com/wp-content/uploads/2025/10/MHRA-Joins-Global-Effort-to-Approve-Promising-Brain-Cancer-Treatment.jpg https://baupharma.com/news-posts/chmp-opinion-paves-way-for-uplizna-in-rare-autoimmune-disease/ 2025-10-02T12:21:20+00:00 https://baupharma.com/wp-content/uploads/2025/10/Article-1.jpg https://baupharma.com/news-posts/fda-takes-bold-step-toward-treating-autism-linked-neurological-condition/ 2025-10-02T12:25:01+00:00 https://baupharma.com/wp-content/uploads/2025/10/Article-3.jpg https://baupharma.com/news-posts/fda-clears-first-subcutaneous-keytruda-a-new-era-for-cancer-care/ 2025-10-02T12:26:58+00:00 https://baupharma.com/wp-content/uploads/2025/10/Article-4.jpg https://baupharma.com/news-posts/mhra-reaffirms-use-of-paracetamol-during-pregnancy/ 2025-10-02T12:29:13+00:00 https://baupharma.com/wp-content/uploads/2025/10/Article-5.jpg https://baupharma.com/news-posts/fda-highlights-new-safety-signals-across-key-drug-classes/ 2025-10-09T11:42:09+00:00 https://baupharma.com/wp-content/uploads/2025/10/FDA-Highlights-New-Safety-Signals-Across-Key-Drug-Classes.jpg https://baupharma.com/news-posts/mhra-reaffirms-rules-on-prescription-weight-loss-medicine-advertising/ 2025-10-09T11:44:18+00:00 https://baupharma.com/wp-content/uploads/2025/10/MHRA-Reaffirms-Rules-on-Prescription-Weight-Loss-Medicine-Advertising.jpg https://baupharma.com/news-posts/pediatric-myopia-under-control-with-essilor-stellest-eyeglass-lense/ 2025-10-09T12:11:06+00:00 https://baupharma.com/wp-content/uploads/2025/10/Pediatric-Myopia-Under-Control-with-Essilor-Stellest-Eyeglass-Lense.jpg https://baupharma.com/news-posts/new-treatment-approval-for-acromegaly-patients-spreading-hope/ 2025-10-09T12:12:55+00:00 https://baupharma.com/wp-content/uploads/2025/10/New-Treatment-Approval-for-Acromegaly-Patients-Spreading-Hope.jpg https://baupharma.com/news-posts/targeting-esr1-mutations-fda-approves-innovative-therapy-imlunestrant/ 2025-10-09T12:19:49+00:00 https://baupharma.com/wp-content/uploads/2025/10/Targeting-ESR1-Mutations-FDA-Approves-Innovative-Therapy-Imlunestrant-e1760012374190.jpg https://baupharma.com/news-posts/fast-track-for-american-generics-fda-pushes-to-bring-drug-production-home/ 2025-10-17T11:22:10+00:00 https://baupharma.com/wp-content/uploads/2025/10/Fast-Track-for-American-Generics.jpg https://baupharma.com/news-posts/new-measures-to-minimize-the-risk-of-suicidal-ideation-with-finasteride-and-dutasteride/ 2025-10-17T11:39:31+00:00 https://baupharma.com/wp-content/uploads/2025/10/New-Measures-to-Minimize-the-Risk-of-Suicidal-Ideation-with-Finasteride-and-Dutasteride-1.jpg https://baupharma.com/news-posts/breaking-barriers-in-lung-cancer-care-lurbinectedin-joins-forces-with-atezolizumab/ 2025-10-20T09:25:50+00:00 https://baupharma.com/wp-content/uploads/2025/10/Approval-ArticleBreaking-Barriers-in-Lung-Cancer-Care-Lurbinectedin-Joins-Forces-with-Atezolizumab.jpg https://baupharma.com/news-posts/fda-moves-to-protect-children-amid-reports-of-toxic-cough-medicines-abroad/ 2025-10-23T11:41:37+00:00 https://baupharma.com/wp-content/uploads/2025/10/FDA-Moves-to-Protect-Children-Amid-Reports-of-Toxic-Cough-Medicines-Abroad.jpg https://baupharma.com/news-posts/fda-expands-libtayos-role-in-cancer-care-with-adjuvant-approval-for-cscc/ 2025-10-23T11:46:42+00:00 https://baupharma.com/wp-content/uploads/2025/10/FDA-Expands-Libtayos-Role-in-Cancer-Care-with-Adjuvant-Approval-for-CSCC.jpg https://baupharma.com/news-posts/ema-issues-warning-on-caspofungin-use-with-pan-membranes/ 2025-10-23T11:48:58+00:00 https://baupharma.com/wp-content/uploads/2025/10/EMA-Issues-Warning-on-Caspofungin-Use-with-PAN-Membranes.jpg https://baupharma.com/news-posts/new-mri-requirement-aims-to-detect-aria-earlier-in-leqembi-therapy/ 2025-10-23T11:51:31+00:00 https://baupharma.com/wp-content/uploads/2025/10/New-MRI-Requirement-Aims-to-Detect-ARIA-Earlier-in-LEQEMBI-Therapy.jpg https://baupharma.com/news-posts/safety-alert-fda-highlights-risks-of-spinal-administration-errors-with-tranexamic-acid/ 2025-10-29T10:45:08+00:00 https://baupharma.com/wp-content/uploads/2025/10/Safety-Alert-FDA-Highlights-Risks-of-Spinal-Administration-Errors-with-Tranexamic-Acid.jpg https://baupharma.com/news-posts/transforming-healthcare-mhra-advances-safe-ai-testing-in-medicine/ 2025-10-29T10:48:50+00:00 https://baupharma.com/wp-content/uploads/2025/10/Transforming-Healthcare-MHRA-Advances-Safe-AI-Testing-in-Medicine.jpg https://baupharma.com/news-posts/artificial-intelligence-takes-aim-at-hidden-risks-in-multi-drug-prescriptions/ 2025-10-29T10:51:08+00:00 https://baupharma.com/wp-content/uploads/2025/10/Artificial-Intelligence-Takes-Aim-at-Hidden-Risks-in-Multi-Drug-Prescriptions.jpg https://baupharma.com/news-posts/uks-new-innovative-licensing-and-access-pathway-ilap/ 2025-10-29T10:53:50+00:00 https://baupharma.com/wp-content/uploads/2025/10/UKs-New-Innovative-Licensing-and-Access-Pathway-ILAP.jpg https://baupharma.com/news-posts/uk-authorities-puts-end-to-largest-illegal-weight-loss-production-facility/ 2025-11-07T12:07:47+00:00 https://baupharma.com/wp-content/uploads/2025/11/UK-Authorities-Puts-End-to-Largest-Illegal-Weight-Loss-Production-Facility.jpg https://baupharma.com/news-posts/concizumab-approval-marks-a-major-step-forward-in-hemophilia-management/ 2025-11-07T12:16:41+00:00 https://baupharma.com/wp-content/uploads/2025/11/Concizumab-Approval-Marks-a-Major-Step-Forward-in-Hemophilia-Management.jpg https://baupharma.com/news-posts/fda-approves-belantamab-mafodotin-blmf-combo-for-refractory-multiple-myeloma/ 2025-11-07T12:19:45+00:00 https://baupharma.com/wp-content/uploads/2025/11/FDA-Approves-Belantamab-Mafodotin-Blmf-Combo-for-Refractory-Multiple-Myeloma.jpg https://baupharma.com/news-posts/fda-approves-revumenib-a-new-hope-for-aml-with-npm1-mutation/ 2025-11-07T12:22:42+00:00 https://baupharma.com/wp-content/uploads/2025/11/FDA-Approves-Revumenib-A-New-Hope-for-AML-with-NPM1-Mutation.jpg https://baupharma.com/news-posts/damaged-lenalidomide-capsules-detected-handling-precautions-being-set/ 2025-11-07T12:25:12+00:00 https://baupharma.com/wp-content/uploads/2025/11/Damaged-Lenalidomide-Capsules-Detected-Handling-Precautions-Being-Set.jpg https://baupharma.com/news-posts/rising-meningitis-threat-in-the-uk-why-vaccination-cant-slip/ 2025-11-13T09:17:44+00:00 https://baupharma.com/wp-content/uploads/2025/11/Rising-Meningitis-Threat-in-the-UK-Why-Vaccination-Cant-Slip.jpg https://baupharma.com/news-posts/mhra-announces-major-reform-to-accelerate-rare-disease-therapies-in-the-uk/ 2025-11-13T09:26:32+00:00 https://baupharma.com/wp-content/uploads/2025/11/MHRA-Announces-Major-Reform-to-Accelerate-Rare-Disease-Therapies-in-the-UK-1.jpg https://baupharma.com/news-posts/a-new-era-for-menopause-care-science-restored-choices-expanded/ 2025-11-24T09:42:23+00:00 https://baupharma.com/wp-content/uploads/2025/11/New-Era-for-Menopause-Care-Science-Restored-Choices-Expanded-e1763977330404.jpg https://baupharma.com/news-posts/new-safety-restrictions-on-elevidys-to-protect-duchenne-muscular-dystrophy-patients/ 2025-11-28T13:35:51+00:00 https://baupharma.com/wp-content/uploads/2025/11/New-Safety-Restrictions-on-Elevidys-to-Protect-Duchenne-Muscular-Dystrophy-Patients.jpg https://baupharma.com/news-posts/new-fda-criteria-for-approving-ph-adjuster-differences-in-generic-drug-applications/ 2025-11-28T13:38:12+00:00 https://baupharma.com/wp-content/uploads/2025/11/New-FDA-Criteria-for-Approving-pH-Adjuster-Differences-in-Generic-Drug-Applications.jpg https://baupharma.com/news-posts/emas-role-in-public-health-crisis-response-health-threats-plan-overview/ 2025-11-28T13:40:15+00:00 https://baupharma.com/wp-content/uploads/2025/11/EMAs-Role-in-Public-Health-Crisis-Response-Health-Threats-Plan-Overview.jpg https://baupharma.com/news-posts/agentic-ai-goes-live-at-fda/ 2025-12-12T09:06:58+00:00 https://baupharma.com/wp-content/uploads/2025/12/Agentic-AI-Goes-Live-at-FDA.jpg https://baupharma.com/news-posts/uk-expert-group-recommends-stronger-warnings-on-antidepressant-risks/ 2025-12-12T09:13:26+00:00 https://baupharma.com/wp-content/uploads/2025/12/UK-Expert-Group-Recommends-Stronger-Warnings-on-Antidepressant-Risks-1.jpg https://baupharma.com/news-posts/fda-qualifies-first-ai-tool-to-speed-mash-drug-development/ 2025-12-19T09:24:34+00:00 https://baupharma.com/wp-content/uploads/2025/12/FDA-qualifies-First-AI-Tool-to-Speed-MASH-Drug-Development.jpg https://baupharma.com/news-posts/hep-b-vaccines-for-infants-mhra-reaffirms-strong-safety-record/ 2025-12-19T09:29:20+00:00 https://baupharma.com/wp-content/uploads/2025/12/Hep-B-Vaccines-for-Infants-MHRA-Reaffirms-Strong-Safety-Record.jpg https://baupharma.com/news-posts/ema-welcomes-landmark-reform-of-eu-pharmaceutical-legislation/ 2025-12-29T17:48:31+00:00 https://baupharma.com/wp-content/uploads/2025/12/EMA-Welcomes-Landmark-Reform-of-EU-Pharmaceutical-Legislation.jpg https://baupharma.com/news-posts/inside-mhra-gcp-inspections-what-you-need-to-know/ 2025-12-29T17:51:03+00:00 https://baupharma.com/wp-content/uploads/2025/12/Inside-MHRA-GCP-Inspections-What-You-Need-to-Know.jpg https://baupharma.com/news-posts/from-variation-to-validation-emas-stability-testing-update/ 2025-12-30T13:25:03+00:00 https://baupharma.com/wp-content/uploads/2025/12/From-Variation-to-Validation-EMAs-Stability-Testing-Update.jpg https://baupharma.com/news-posts/fda-opens-the-door-to-broader-use-of-real-world-evidence/ 2025-12-30T13:27:04+00:00 https://baupharma.com/wp-content/uploads/2025/12/FDA-Opens-the-Door-to-Broader-Use-of-Real-World-Evidence.jpg https://baupharma.com/news-posts/navigating-the-real-world-safety-landscape-of-esketamine-therapy/ 2026-01-08T14:15:11+00:00 https://baupharma.com/wp-content/uploads/2026/01/Navigating-the-Real-World-Safety-Landscape-of-Esketamine-Therap-1.jpg https://baupharma.com/news-posts/smarter-healthcare-systems-the-role-of-big-data-and-machine-learning/ 2026-01-08T14:20:10+00:00 https://baupharma.com/wp-content/uploads/2026/01/Smarter-Healthcare-Systems-The-Role-of-Big-Data-and-Machine-Learning.jpg https://baupharma.com/news-posts/label-update-fda-requests-removal-of-suicidal-ideation-and-behavior-warning-for-glp-1-weight-management-drugs/ 2026-01-23T23:47:07+00:00 https://baupharma.com/wp-content/uploads/2026/01/FDA-Requests-Removal-of-Suicidal-Ideation.jpg https://baupharma.com/news-posts/hidden-signals-in-routine-antibiotics-drug-eruption-risks-revealed-by-pharmacovigilance/ 2026-01-23T23:50:21+00:00 https://baupharma.com/wp-content/uploads/2026/01/Hidden-Signals-in-Routine-Antibiotics-website-scaled.jpg https://baupharma.com/news-posts/from-innovation-to-regulation-a-framework-for-good-ai-practice-in-pharma/ 2026-01-28T22:29:32+00:00 https://baupharma.com/wp-content/uploads/2026/01/From-Innovation-to-Regulation-A-Framework-for-Good-AI-Practice-in-Pharma.jpg https://baupharma.com/news-posts/doorstep-vaccines-uk-nhs-pilot-2026/ 2026-01-30T11:31:56+00:00 https://baupharma.com/wp-content/uploads/2026/01/Doorstep-Vaccines-New-UK-Pilot-Delivers-Protection-Directly-to-At-Risk-Families.jpg https://baupharma.com/news-posts/fda-faers-in-focus-quarterly-alerts-on-potential-drug-safety-risks/ 2026-01-30T11:33:23+00:00 https://baupharma.com/wp-content/uploads/2026/01/FAERS-in-Focus-FDAs-Quarterly-Alerts-on-Potential-Drug-Safety-Risks.jpg https://baupharma.com/news-posts/new-lancet-review-strengthens-guidance-on-paracetamol-use-in-pregnancy/ 2026-02-04T10:06:16+00:00 https://baupharma.com/wp-content/uploads/2026/01/New-Lancet-Review-Strengthens-Guidance-on-Paracetamol-Use-in-Pregnancy.jpg https://baupharma.com/news-posts/ich-e22-patient-preference-webinar/ 2026-02-15T23:00:30+00:00 https://baupharma.com/wp-content/uploads/2026/02/ICH-Events-ICH-E22-Patient-Preference-Studies-Webinar.jpg https://baupharma.com/news-posts/european-medicines-agency-ema-chmp-meeting-highlights-26-29-january-2026/ 2026-02-15T23:01:26+00:00 https://baupharma.com/wp-content/uploads/2026/02/European-Medicines-Agency-EMA-CHMP-Meeting-Highlights-%E2%80%93-26%E2%80%9329-January-2026.jpg https://baupharma.com/news-posts/nmpa-strengthens-drug-regulation-under-revised-drug-administration-rules/ 2026-02-15T23:08:10+00:00 https://baupharma.com/wp-content/uploads/2026/02/NMPA-Strengthen-Drug-Regulation-Under-Revised-Drug-Administration-Rules.jpg https://baupharma.com/news-posts/a-fast-track-for-the-future-mhra-nice-launch-aligned-pathway-early/ 2026-02-21T10:18:46+00:00 https://baupharma.com/wp-content/uploads/2025/10/A-Fast-Track-for-the-Future-MHRA-NICE-Launch-Aligned-Pathway-Early.jpg https://baupharma.com/news-posts/a-major-step-forward-uk-first-approval-for-friedreichs-ataxia-condition/ 2026-02-21T10:21:19+00:00 https://baupharma.com/wp-content/uploads/2025/05/UK-Approval-for-specific-Ataxia-condition.jpg https://baupharma.com/news-posts/a-new-conditionally-approved-treatment-for-patients-with-lymphoblastic-leukemia/ 2026-02-21T10:23:44+00:00 https://baupharma.com/wp-content/uploads/2025/06/A-new-Conditionally-Approved-treatment-for-patients-with-lymphoblastic-leukemia.jpg https://baupharma.com/news-posts/a-new-hope-for-patients-suffering-from-dystrophic-epidermolysis-bullosa/ 2026-02-21T10:27:12+00:00 https://baupharma.com/wp-content/uploads/2025/04/A-New-Hope-for-Patients-Suffering-from-Dystrophic-Epidermolysis-Bullosa.jpg https://baupharma.com/news-posts/a-rare-breakthrough-first-fda-approved-treatment-for-barth-syndrome/ 2026-02-21T10:29:20+00:00 https://baupharma.com/wp-content/uploads/2025/10/Article-2.jpg https://baupharma.com/news-posts/a-wake-up-call-for-microbiome-science-mhra-highlights-global-variability/ 2026-02-21T10:40:01+00:00 https://baupharma.com/wp-content/uploads/2025/11/A-Wake-Up-Call-for-Microbiome-Science-MHRA-Highlights-Global-Variability.jpg https://baupharma.com/news-posts/abu-dhabi-global-healthcare-week-2024-pioneering-the-future-of-global-health/ 2026-02-21T10:45:28+00:00 https://baupharma.com/wp-content/uploads/2023/08/business-partners-team-walking-down-discussing-work-scaled.jpeg https://baupharma.com/news-posts/advancing-vaccine-and-medicine-safety-in-low-and-middle-income-countries/ 2026-02-21T10:48:09+00:00 https://baupharma.com/wp-content/uploads/2025/12/Advancing-Vaccine-and-Medicine-Safety-in-Low-and-Middle-Income-Countries.jpg https://baupharma.com/news-posts/advancing-vaccine-safety-unveiling-the-vaccine-monitoring-platform-research-agenda/ 2026-02-21T10:55:57+00:00 https://baupharma.com/wp-content/uploads/2023/09/close-up-chief-researcher-scientist-adjusts-microscope-time-coronavirus-experiment-scaled.jpeg https://baupharma.com/news-posts/anticholinergic-burden-and-adverse-drug-reactions-real-world-evidence-from-the-french-pharmacovigilance-database/ 2026-02-21T10:58:58+00:00 https://baupharma.com/wp-content/uploads/2026/01/True-Anticholinergic-Burden-in-French-PV-Data-scaled.jpg https://baupharma.com/news-posts/eda-public-consultation-biological-products-registration-guideline-2026/ 2026-02-21T20:13:38+00:00 https://baupharma.com/wp-content/uploads/2026/02/Egyptian-Drug-Authority-Announces-Public-Consultation-on-Draft-Guideline-for-Biological-Products-Registration.jpg https://baupharma.com/news-posts/saeed-bin-mubarak-al-hajeri-launches-emirates-drug-establishment-whx-2026/ 2026-02-21T20:20:04+00:00 https://baupharma.com/wp-content/uploads/2026/02/Saeed-bin-Mubarak-Al-Hajeri-Launches-Emirates-Drug-Establishment-at-World-Health-Expo-2026.jpg https://baupharma.com/news-posts/ema-levamisole-withdrawal-eu-2026/ 2026-02-27T14:40:43+00:00 https://baupharma.com/wp-content/uploads/2026/02/EMA-Recommends-Withdrawal-of-Levamisole-Medicines-in-the-EU.jpg https://baupharma.com/news-posts/kazakhstan-nce-holds-pharmacovigilance-seminar-2026/ 2026-02-27T14:54:43+00:00 https://baupharma.com/wp-content/uploads/2026/02/Kazakhstan-NCE-Holds-Pharmacovigilance-Seminar.jpg https://baupharma.com/news-posts/sukl-export-notification-dis-18-section-77c-2026/ 2026-02-27T14:58:42+00:00 https://baupharma.com/wp-content/uploads/2026/02/SUKL-Reminds-Distributors-of-Export-Notification-Duties.jpg https://baupharma.com/news-posts/philippine-fda-regulatory-action-major-retailers/ 2026-03-06T23:51:25+00:00 https://baupharma.com/wp-content/uploads/2026/03/Philippine-FDA-Places-Major-Retailers-Under-Regulatory-Scrutiny-Over-Non-Compliant-Products.jpg https://baupharma.com/news-posts/swedish-medicines-agency-annual-report-2025/ 2026-03-06T23:56:24+00:00 https://baupharma.com/wp-content/uploads/2026/03/The-Swedish-Medicines-Agencys-Annual-Report-for-2025.jpg https://baupharma.com/news-posts/sg-ectd-version-1-1-singapore-update/ 2026-03-13T18:49:35+00:00 https://baupharma.com/wp-content/uploads/2026/03/SG-eCTD.jpg https://baupharma.com/news-posts/kazakhstan-who-regulatory-system-assessment/ 2026-03-13T19:07:37+00:00 https://baupharma.com/wp-content/uploads/2026/03/Kazakhstan-Summarizes-Results-of-WHO-Mission-to-Assess-the-Regulatory-System.jpeg https://baupharma.com/news-posts/ema-3rswp-stakeholder-meeting-2026-2028/ 2026-03-13T19:15:41+00:00 https://baupharma.com/wp-content/uploads/2026/03/EMA-3RsWP-Stakeholder-Meeting-on-2026%E2%80%932028-Work-Plan.jpg https://baupharma.com/news-posts/fda-ich-m14-guidance-non-interventional-studies-rwd/ 2026-03-13T19:20:41+00:00 https://baupharma.com/wp-content/uploads/2026/03/FDA-Releases-ICH-M14-Guidance-on-Non-Interventional-Studies-Using-Real-World-Data.jpg https://baupharma.com/news-posts/fda-ich-e2dr1-post-approval-safety-data-guidance/ 2026-03-17T17:08:44+00:00 https://baupharma.com/wp-content/uploads/2026/03/ICH-E2DR1-website-Image-Article-6.jpg https://baupharma.com/news-posts/clinical-trials-guidance-eu-public-health-emergencies/ 2026-03-19T14:37:57+00:00 https://baupharma.com/wp-content/uploads/2026/03/Accelerating-Clinical-Trials-in-the-EU-During-Public-Health-Emergencies-EMA-Draft-Guidance.jpg https://baupharma.com/news-posts/fda-adverse-event-monitoring-system-aems/ 2026-03-27T13:06:04+00:00 https://baupharma.com/wp-content/uploads/2026/03/FDA-Launches-New-Adverse-Event-Monitoring-System-AEMS.jpg https://baupharma.com/news-posts/spain-pharmacovigilance-report-2025/ 2026-04-06T04:15:04+00:00 https://baupharma.com/wp-content/uploads/2026/04/Spain-Reports-Increase-in-Adverse-Drug-Reactions-in-2025-Pharmacovigilance-Annual-Report.jpg https://baupharma.com/news-posts/moldova-gmp-rules-medicine-quality/ 2026-04-06T04:19:44+00:00 https://baupharma.com/wp-content/uploads/2026/04/Spain-Reports-Increase-in-Adverse-Drug-Reactions-in-2025-Pharmacovigilance-Annual-Report-1.jpg https://baupharma.com/news-posts/ema-prime-tools-medicine-development-eu/ 2026-04-06T04:24:37+00:00 https://baupharma.com/wp-content/uploads/2026/04/EMA-Introduces-New-PRIME-Tools-to-Accelerate-Medicine-Development-in-the-EU.jpg https://baupharma.com/news-posts/estonia-accelerated-clinical-trials-fast-eu/ 2026-04-13T12:44:30+00:00 https://baupharma.com/wp-content/uploads/2026/04/Estonia-Introduces-Accelerated-Assessment-Procedures-to-Support-Clinical-Trials.jpg https://baupharma.com/news-posts/animal-derived-materials-labelling-npra-update/ 2026-05-03T11:45:44+00:00 https://baupharma.com/wp-content/uploads/2026/05/Analytical-testing-web-image.jpg https://baupharma.com/news-posts/iris-icd11-transition-strategy/ 2026-05-03T11:50:07+00:00 https://baupharma.com/wp-content/uploads/2026/05/Iris-and-ICD-11-Strategy-Transition-and-Evaluation-Activities.jpg https://baupharma.com/news-posts/lithuania-sunset-clause-medicinal-products-2026/ 2026-05-03T11:57:08+00:00 https://baupharma.com/wp-content/uploads/2026/05/Lithuania-Regulatory-Update-on-Sunset-Clause-for-Medicinal-Products.jpg https://baupharma.com/news-posts/belgium-launches-hemovigilance-online-application/ 2026-05-06T09:10:39+00:00 https://baupharma.com/wp-content/uploads/2026/03/Belgium-Launches-New-Online-HemoVigilance-Application.jpg https://baupharma.com/news-posts/malaysia-certificate-indication-declaration-form-update/ 2026-05-06T09:17:30+00:00 https://baupharma.com/wp-content/uploads/2026/05/Malaysia-Updates-Application-Form-for-Certificate-of-Indication-and-Declaration-1.jpg https://baupharma.com/news-posts/fda-genome-editing-safety-guidance/ 2026-05-06T09:22:22+00:00 https://baupharma.com/wp-content/uploads/2026/05/FDA-Issues-Draft-Guidance-on-Genome-Editing-Safety-Standards-to-Support-Gene-Therapy-Development.jpg https://baupharma.com/news-posts/chmp-meeting-highlights-march-2026/ 2026-05-06T09:27:37+00:00 https://baupharma.com/wp-content/uploads/2026/04/CHMP-Meeting-Highlights-23%E2%80%9326-March-2026.jpg https://baupharma.com/news-posts/aemps-december-2025-drug-safety-bulletin/ 2026-05-06T09:43:53+00:00 https://baupharma.com/wp-content/uploads/2026/03/Spains-AEMPS-Publishes-December-2025-Safety-Bulletin.jpeg https://baupharma.com/news-posts/tga-upgrades-medicine-adverse-event-database/ 2026-05-06T11:25:56+00:00 https://baupharma.com/wp-content/uploads/2026/02/TGA-Upgrades-Internal-Database-for-Medicine-Adverse-Events-Reports.jpg https://baupharma.com/news-posts/npra-inspection-dashboard-malaysia/ 2026-05-10T14:31:06+00:00 https://baupharma.com/wp-content/uploads/2026/05/NPRA.jpg https://baupharma.com/news-posts/taiwan-clinical-trial-guidelines-extracellular-preparations/ 2026-05-10T14:43:09+00:00 https://baupharma.com/wp-content/uploads/2026/05/Taiwan-Issues-Guidelines-for-Clinical-Trial-Applications-of-Human-Extracellular-Preparations.jpg https://baupharma.com/news-posts/uae-ai-drug-discovery-insilico-medicine/ 2026-05-10T14:46:00+00:00 https://baupharma.com/wp-content/uploads/2026/05/UAE-Advances-AI-Driven-Drug-Development-with-First-Locally-Discovered-Candidate.webp https://baupharma.com/news-posts/fda-real-time-clinical-trials-initiative/ 2026-05-10T14:49:45+00:00 https://baupharma.com/wp-content/uploads/2026/05/FDA-Advances-Implementation-of-Real-Time-Clinical-Trials.jpg https://baupharma.com/news-posts/ema-vaccine-confidence-advisory-group/ 2026-05-17T21:25:01+00:00 https://baupharma.com/wp-content/uploads/2026/05/EMA-Launches-New-Advisory-Group-on-Vaccine-Confidence.jpg https://baupharma.com/news-posts/singapore-ectd-cmc-declaration-update-2026/ 2026-05-19T15:42:26+00:00 https://baupharma.com/wp-content/uploads/2026/04/Singapore-Updates-Therapeutic-Product-Registration-with-eCTD-Adoption-and-CMC-Declaration-Requirement.jpg https://baupharma.com/news-posts/ich-m11-cesharp-final-overview-presentation/ 2026-05-22T12:08:01+00:00 https://baupharma.com/wp-content/uploads/2026/05/ICH-M11-Expert-Working-Group-Issues-Final-Presentation-for-Clinical-Trial-Protocol-Standardisation-scaled.jpg https://baupharma.com/news-posts/fda-pregnancy-safety-studies-guidance/ 2026-05-22T12:10:41+00:00 https://baupharma.com/wp-content/uploads/2026/05/FDA-Issues-Guidance-to-Improve-Collection-of-Pregnancy-Safety-Data-for-Drugs-and-Biologics-scaled.jpg https://baupharma.com/news-posts/china-adr-monitoring-annual-report-2025/ 2026-05-22T16:43:40+00:00 https://baupharma.com/wp-content/uploads/2026/05/China-Releases-National-Adverse-Drug-Reaction-Monitoring-Annual-Report-2025-3.jpg https://baupharma.com/news-posts/czech-republic-clinical-trials-2025/ 2026-06-05T12:26:58+00:00 https://baupharma.com/wp-content/uploads/2026/06/Czech-Republic-Highlights-Clinical-Trial-Activities-and-Regulatory-Developments-in-2025.jpg https://baupharma.com/news-posts/rare-disease-therapies-regulatory-framework-consultation/ 2026-06-05T12:29:30+00:00 https://baupharma.com/wp-content/uploads/2026/06/MHRA-Launches-Consultation-on-Draft-Rare-Disease-Therapies-Regulatory-Framework.jpg https://baupharma.com/news-posts/mhra-ai-sandbox-medicines-development-safety/ 2026-06-21T21:37:01+00:00 https://baupharma.com/wp-content/uploads/2026/06/MHRA-Explores-AI-Driven-Approaches-to-Strengthen-Medicines-Safety-and-Development.jpg https://baupharma.com/news-posts/denmark-updates-guidance-digital-decentralised-clinical-trials/ 2026-06-21T21:39:59+00:00 https://baupharma.com/wp-content/uploads/2026/06/Denmark-Updates-Guidance-on-Digital-and-Decentralised-Clinical-Trials.jpg https://baupharma.com/news-posts/fda-generic-drug-quality-oversight-access/ 2026-06-21T21:42:32+00:00 https://baupharma.com/wp-content/uploads/2026/06/FDA-Highlights-Generic-Drug-Oversight-to-Ensure-Quality-and-Expand-Patient-Access.jpg https://baupharma.com/news-posts/china-good-clinical-practice-guidelines-2026/ 2026-06-26T20:42:02+00:00 https://baupharma.com/wp-content/uploads/2026/06/China-Issues-Revised-Good-Clinical-Practice-Guidelines-for-Drug-Clinical-Trials.jpg https://baupharma.com/news-posts/fda-permits-marketing-of-first-point-of-care-hepatitis-c-rna-test/ 2026-09-17T09:54:38+00:00 https://baupharma.com/wp-content/uploads/2024/07/FDA-Permits-Marketing-of-First-Point-of-Care-Hepatitis-C-RNA-Test.jpg https://baupharma.com/news-posts/machine-learning-pediatric-pharmacovigilance-safety-signals/ 2026-09-17T09:57:30+00:00 https://baupharma.com/wp-content/uploads/2026/01/The-Future-of-Child-Health-Machine-Learning-Uncovers-Unique-Pediatric-Drug-Reactions.jpg https://baupharma.com/news-posts/new-ema-rules-easier-admin-tweaks-smarter-quality-variations/ 2026-09-17T09:58:56+00:00 https://baupharma.com/wp-content/uploads/2025/12/New-EMA-Rules-Easier-Admin-Tweaks-Smarter-Quality-Variations.jpg https://baupharma.com/news-posts/new-sfda-approval-brings-diagnostic-devices-for-antipsychotic-blood-monitoring/ 2026-09-17T09:59:42+00:00 https://baupharma.com/wp-content/uploads/2025/09/New-SFDA-Approval-Brings-Diagnostic-Devices-for-Antipsychotic-Blood-Monitoring.jpg https://baupharma.com/news-posts/precision-meets-innovation-sfda-endorses-real-time-brain-stimulation-technology-for-parkinsons-disease/ 2026-09-17T10:01:38+00:00 https://baupharma.com/wp-content/uploads/2025/08/Precision-Meets-Innovation-SFDA-Endorses-Real-Time-Brain-Stimulation-Technology-for-Parkinsons-Disease.jpg https://baupharma.com/news-posts/rasid-empowering-saudi-arabia-with-cutting-edge-ai-for-smarter-drug-regulation/ 2026-09-17T10:02:18+00:00 https://baupharma.com/wp-content/uploads/2025/11/RASID-Empowering-Saudi-Arabia-with-Cutting-Edge-AI-for-Smarter-Drug-Regulation.jpg https://baupharma.com/news-posts/safety-update-on-epimax-ointment-and-epimax-paraffin-free-ointment-reports-of-ocular-surface-toxicity-and-ocular-chemical-injury/ 2026-09-17T10:04:15+00:00 https://baupharma.com/wp-content/uploads/2024/07/Safety-update-on-Epimax-Ointment-and-Epimax-Paraffin-Free-Ointment.png https://baupharma.com/news-posts/saudi-arabia-advances-drug-safety-with-sfda-digital-integration/ 2026-09-17T10:04:53+00:00 https://baupharma.com/wp-content/uploads/2025/11/Saudi-Arabia-Advances-Drug-Safety-with-SFDA-Digital-Integration.jpg https://baupharma.com/news-posts/saudi-arabia-joins-whos-global-drug-safety-hub/ 2026-09-17T10:05:36+00:00 https://baupharma.com/wp-content/uploads/2025/12/Saudi-Arabia-Joins-WHOs-Global-Drug-Safety-Hub.jpg https://baupharma.com/news-posts/saudi-arabia-unveils-the-saudi-pharmacopoeia-defining-a-new-regulatory-benchmark/ 2026-09-17T10:06:16+00:00 https://baupharma.com/wp-content/uploads/2025/11/Saudi-Arabia-Unveils-the-Saudi-Pharmacopoeia-Defining-a-New-Regulatory-Benchmark.jpg https://baupharma.com/news-posts/sfda-discusses-strengthening-implementation-of-the-drug-track-and-trace-system-rsd/ 2026-09-17T10:09:22+00:00 https://baupharma.com/wp-content/uploads/2026/01/SFDA.jpg https://baupharma.com/news-posts/sfda-enhances-global-engagement-with-new-ich-information-hub/ 2026-09-17T10:12:42+00:00 https://baupharma.com/wp-content/uploads/2025/10/SFDA-Enhances-Global-Engagement-with-New-ICH-Information-Hub-1.jpg https://baupharma.com/news-posts/sfda-fast-tracks-access-to-qalsody-under-the-orphan-drug-program/ 2026-09-17T10:13:42+00:00 https://baupharma.com/wp-content/uploads/2025/10/SFDA-Fast-Tracks-Access-to-Qalsody-Under-the-Orphan-Drug-Program.jpg https://baupharma.com/news-posts/sfda-launches-safety-network-to-protect-mothers-and-newborns/ 2026-09-17T10:22:11+00:00 https://baupharma.com/wp-content/uploads/2025/11/SFDA-Launches-Safety-Network-to-Protect-Mothers-and-Newborns.jpg https://baupharma.com/news-posts/sfda-reports-18-growth-in-licensed-factories-and-warehouses-during-2025/ 2026-09-17T10:23:06+00:00 https://baupharma.com/wp-content/uploads/2026/02/SFDA-Reports-18-Growth-in-Licensed-Factories-and-Warehouses-During-2025.png